{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:14:06Z","timestamp":1760145246046,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Cost-effectiveness analyses are required for therapies within Canada\u2019s universal healthcare system, leading to delays relative to U.S. healthcare. Patients with Hodgkin lymphoma (HL) generally have an excellent prognosis, but those who relapse after or are ineligible for transplant benefit from novel therapies, including brentuximab vedotin (BV). BV was FDA-approved in 2011 but not Canadian-funded until 2014. To assess the impact of access delays, we compared changes in survival for U.S. (by insurer) and Canadian patients in periods pre\/post-U.S. approval. Patients were 16\u201364 years, diagnosed with HL in 2007\u20132010 (Period 1) and 2011\u20132014 (Period 2) from the U.S. SEER and Canadian Cancer Registries. Approval date (surrogate) was utilized as therapy was unavailable in registries. Kaplan-Meier survival curves and adjusted Cox regression models compared survival between periods by insurance category. Among 12,003 U.S. and 4210 Canadian patients, survival was better in U.S. patients (adjusted hazard ratio (aHR) 0.87 (95%CI 0.77\u20130.98)) between periods; improvement in Canadian patients (aHR 0.84 (95%CI 0.69\u20131.03) was similar but non-significant. Comparisons between insurers showed survival was significantly worse for U.S. uninsured and Medicaid vs. U.S. privately insured and Canadian patients. Given the increasingly complex nature of oncologic funding, this merits further investigation to ensure equity in access to therapy developments.<\/jats:p>","DOI":"10.3390\/curroncol31070287","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T06:28:54Z","timestamp":1720074534000},"page":"3885-3894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed\/Refractory Disease: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"31","author":[{"given":"Gwynivere A.","family":"Davies","sequence":"first","affiliation":[{"name":"Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada"},{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Orav","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-4775","authenticated-orcid":false,"given":"Kristen D.","family":"Brantley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1200\/JCO.2014.55.6258","article-title":"Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status","volume":"32","author":"Walker","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1634\/theoncologist.2015-0228","article-title":"Health Insurance-Related Disparities in Lymphoma Survival Are Partly Mediated by Baseline Clinical Factors","volume":"20","author":"Olszewski","year":"2015","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1634\/theoncologist.2014-0386","article-title":"Survival disparities by insurance type for patients aged 15\u201364 years with non-Hodgkin lymphoma","volume":"20","author":"Pulte","year":"2015","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clml.2017.05.011","article-title":"Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia","volume":"17","author":"Srour","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/10428194.2018.1520987","article-title":"Association of insurance status with survival in patients with cutaneous T-cell lymphoma","volume":"60","author":"Tang","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/theoncologist.2011-0126","article-title":"Cancer disparities in the context of Medicaid insurance: A comparison of survival for acute myeloid leukemia and Hodgkin\u2019s lymphoma by Medicaid enrollment","volume":"16","author":"Yung","year":"2011","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cam4.84","article-title":"Cancer survival disparities by health insurance status","volume":"2","author":"Niu","year":"2013","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/curroncol31040136","article-title":"Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement","volume":"31","author":"Sehdev","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_11","first-page":"9492","article-title":"New cancer drugs in Canada 2012 to 2021: An economic analysis of cost, benefit, availability, and public insurance coverage","volume":"2562","author":"Skinner","year":"2023","journal-title":"Can. Health Policy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_13","unstructured":"Canadian Cancer Statistics Advisory Committee (2023). Canadian Cancer Statistics, The Canadian Cancer Society. Available online: https:\/\/cancer.ca\/en\/research\/cancer-statistics."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_15","unstructured":"Pan-Canadian Oncology Drug Review (2018). Initial Economic Guidance Report\u2014Brentuximab (Adcentris) for Hodgkin Lymphoma (Resubmission), Pan-Canadian Oncology Drug Review. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_brentuximab_adcetris_hl_post-asct_resub_in_egr.pdf."},{"key":"ref_16","unstructured":"National Cancer Institute (2024, May 28). Surveillance, Epidemiology and End Results (SEER): Surveillance Research Program Overview, Available online: https:\/\/seer.cancer.gov\/about\/factsheets\/SEER_Overview.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison with the General Population in British Columbia","volume":"34","author":"Hapgood","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.3390\/curroncol30070469","article-title":"The Impact of Medicaid Expansion on Patients with Cancer in the United States: A Review","volume":"30","author":"Hotca","year":"2023","journal-title":"Curr. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:10:02Z","timestamp":1760109002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["curroncol31070287"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31070287","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}